Regeneron Pharmaceuticals, Inc. (REGN) Q1 2008 Earnings Results

Regeneron Pharmaceuticals Misses on EPS, Stock Down 1.9%

Regeneron's earnings report showed a loss per share, which contributed to a 1.9% drop in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's short-term performance. Management's cautious tone suggests they are navigating through challenges but remain focused on future growth.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.15	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding the current market conditions. They emphasized their commitment to innovation and long-term goals.

Management did not provide specific revenue guidance for the upcoming quarters.

The company remains focused on its long-term growth strategy despite the current challenges.

Regeneron Pharmaceuticals Misses on EPS, Stock Down 1.9%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Misses on EPS, Stock Down 1.9%

Key numbers

Management commentary